

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTB

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 09/831,047 |
| Filing Date | May 3, 2001 |
| First Named Inventor | Biasczyk-Thurin |
| Art Unit | 1653 |
| Examiner Name | S. Snedden |
| Attorney Docket Number | WST93AUSA |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|

[illegible][illegible]

**Examiner
Signature**

| | |
|-----------------|--|
| Date Considered | |
|-----------------|--|

9/2/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | | |
|---|---|--------------------------|------------------|------------------------|-----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/831,047 | | |
| | | Filing Date | May 3, 2001 | | |
| | | First Named Inventor | Blaszczyk-Thurin | | |
| | | Group Art Unit | 1653 | | |
| | | Examiner Name | S. Snedden | | |
| Sheet | 2 | of | 4 | Attorney Docket Number | WST93AUSA |

| NONPATENT LITERATURE DOCUMENTS | | | |
|--------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include the name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| SS | BBZ | BECHTEL et al., "Conformational analysis of the tumor-associated carbohydrate antigen 19-9 and its Lea blood group antigen component as related to the specificity of monoclonal antibody CO19-9", <i>J. Biol. Chem.</i> February 5, 1990 265(4):2028-2037 | |
| | CR | BLASZCZYK et al., "Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies", <i>Cancer Res.</i> January 1984 44(1):245-253 | |
| | CS | BLASZCZYK et al., "Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas", <i>Proc. Natl. Acad. Sci. USA</i> June 1985 82(11):3552-3556 | |
| | CT | BLASZCZYK et al., "Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies", <i>Arch. Biochem. Biophys.</i> August 15, 1984 233(1):161-168 | |
| | CU | BLASZCZYK-THURIN et al., "Biosynthetic pathways for the Leb and Y glycolipids in the gastric carcinoma cell line KATO III as analyzed by a novel assay", <i>Biochem. Biophys. Res. Commun.</i> February 29, 1988 151(1):100-108 | |
| | CV | BLASZCZYK-THURIN et al., "Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy", <i>J. Biol. Chem.</i> January 5, 1987 262(1):372-379 | |
| | CW | FUKUSHI et al., "Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6", <i>Cancer Res.</i> August 1985 45(8):3711-3717 | |
| SS | CX | GENG et al., "Lectin domain peptides from selectins interact with both cell surface ligands and Ca ²⁺ ions", <i>J. Biol. Chem.</i> October 5, 1992 267(28):19846-19853 | |


| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 9/2/04 |
|--------------------|--|-----------------|--------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------|------------------------|-----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 09/831,047 | | |
| | | Filing Date | May 3, 2001 | | |
| | | First Named Inventor | Błaszczuk-Thurin | | |
| | | Group Art Unit | 1653 | | |
| | | Examiner Name | S. Snedden | | |
| Sheet | 3 | of | 4 | Attorney Docket Number | WST93AUSA |

| NONPATENT LITERATURE DOCUMENTS | | | |
|--------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| SS | CY | HANSSON et al., "Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens. Characterization by antibody binding to glycosphingolipids in a chromatogram binding assay", <i>J. Biol. Chem.</i> April 10, 1983 258(7):4091-4097 | |
| | CZ | HOESS et al., "Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3", <i>Gene</i> June 15, 1993 128(1):43-49 | |
| | CCR | KAUR et al., "Topological analysis of the functional mimicry between a peptide and a carbohydrate moiety", <i>J. Biol. Chem.</i> February 28, 1997 272(9):5539-5543 | |
| | CCS | MAGNANI et al., "A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma", <i>Science</i> April 3, 1981 212(4490):55-56 | |
| | CCT | MARTENS et al., "Peptides which bind to E-selectin and block neutrophil adhesion", <i>J. Biol. Chem.</i> September 8, 1995 270(36):21129-21136 | |
| | CCU | MURALI et al., "Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody", <i>J. Mol. Recogn.</i> November-December 1997 10(6):269-276 | |
| | CCV | PASTAN et al., "Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas", <i>Cancer Res.</i> July 15, 1991 51(14):3781-3787 | |
| | CCW | RAO et al., "Sialyl Lewis X mimics derived from a pharmacophore search are selectin inhibitors with anti-inflammatory activity", <i>J. Biol. Chem.</i> August 5, 1994 269(31):19663-19666 | |
| SS | CCX | RODECK et al., "A mucin containing the X, Y, and H type 2 carbohydrate determinants is shed by carcinoma cells", <i>Hybridoma</i> August 1987 6(4):389-401 | |

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 9/2/04 |
|--------------------|--|-----------------|--------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

